GlassScriptPhysician profile
Charles David Hitson
NPI 1407850480
$3,148.12
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $778 · 2021: $1,277 · 2022: $19.85 · 2023: $14.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $482.87 | 2019-2021 | |
| Amgen INC. | $401.55 | 2019-2021 | |
| Pfizer INC. | $343.99 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $331.54 | 2019-2023 | Breztri |
| Amarin Pharma, INC. | $214.13 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.06 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $128.23 | 2019-2021 | |
| Novo Nordisk INC | $119.90 | 2020-2021 | |
| Abbvie INC. | $94.42 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $84.38 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $79.28 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.05 | 2019-2021 | |
| Biogen, INC. | $67.88 | 2021 | |
| Mylan Specialty L.P. | $58.31 | 2019-2021 | |
| Lilly USA, LLC | $48.08 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.91 | 2021 | |
| Avanir Pharmaceuticals, INC. | $35.11 | 2021 | |
| Boston Scientific Corporation | $34.97 | 2020-2021 | |
| Genentech USA, INC. | $27.51 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $27.07 | 2021 | |
| Merck Sharp & Dohme LLC | $26.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.95 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.75 | 2019-2021 | |
| Allergan, INC. | $24.49 | 2020 | |
| Shire North American Group INC | $22.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.30 | 2020 | |
| Daiichi Sankyo INC. | $19.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.40 | 2021 | |
| Sanofi Pasteur INC. | $15.04 | 2020 | |
| Jazz Pharmaceuticals INC. | $15.04 | 2021 | |
| Dexcom, INC. | $13.50 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.17 | 2021 | |
| Antares Pharma, INC. | $12.97 | 2021 | |
| Clarus Therapeutics INC. | $12.30 | 2021 | |
| Glaxosmithkline, LLC. | $11.92 | 2021 | |
| Nevro Corp. | $11.84 | 2021 | |
| Medtronic, INC. | $11.76 | 2021 | |
| Smith+Nephew, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hitson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.